BRAWN BIOTECH LTD.

Brawn Biotech Ltd has issued letters to shareholders who have not registered their email addresses, providing the weblink to access the Notice of the 41st Annual General Meeting and the Annual Report for the financial year 2025-26. This action is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and supports the Green Initiative. Shareholders without registered emails can access these documents via the company website, stock exchange website, or NSDL/CDSL e-voting portals. Additionally, the company is facilitating a special window for re-lodgement of physical share certificates rejected before April 1, 2019, in accordance with SEBI circulars.

Brawn Biotech Ltd has filed its Annual Report for FY 2025-26 and announced the 41st Annual General Meeting (AGM) scheduled for September 29, 2026. The AGM will be conducted via Video Conferencing/Other Audio Visual Means. Key agenda items include the adoption of audited financial statements, re-appointment of a director retiring by rotation, and the appointment of new statutory auditors. The company also detailed the e-voting timelines, with the cut-off date on September 22, 2026, and e-voting open from September 26 to September 28, 2026. Additionally, the AGM notice includes a special business item to approve managerial remuneration for Mr. Amit Kumar, amounting to ₹9,76,512 per annum for three years.

Brawn Biotech Ltd has issued a notice for its 41st Annual General Meeting (AGM) scheduled for September 29, 2026. The meeting will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company will present the Audited Financial Statements for FY 2025-26, along with the Directors' and Auditors' reports. Key agenda items include the appointment of a director retiring by rotation and the appointment of statutory auditors. Additionally, the AGM will consider and approve managerial remuneration for Mr. Amit Kumar, Manager (KMP), amounting to ₹9,76,512 per annum for three years. The notice also details the timelines for remote e-voting, with the cut-off date on September 22, 2026, and voting open from September 26 to September 28, 2026.

Brawn Biotech Ltd's Board of Directors met on August 13, 2026, and approved the un-audited financial results for the quarter ended June 30, 2026. The board also recommended the appointment of M/s GD S M and Co as Statutory Auditors for a five-year term. Additionally, the board approved convening the 41st Annual General Meeting on September 29, 2026, through VC/OAVM, and approved the Board's Report for the financial year ended March 31, 2026. The meeting commenced at 12:30 PM IST and concluded at 1:00 PM IST.

Brawn Biotech Ltd announced that its Board of Directors, following recommendations from the Audit Committee, has approved the unaudited financial results for the quarter ended June 30, 2026. The board also recommended the appointment of M/s GD S M and Co as Statutory Auditors for a five-year term. Additionally, the company will convene its 41st Annual General Meeting on September 29, 2026, via VC/OAVM, and has approved the Board's Report for the financial year ended March 31, 2026. The meeting was held on August 13, 2026.

Brawn Biotech Ltd has announced that its Board of Directors will convene on August 13, 2026. The primary agenda item for this meeting is to consider and approve the company's Un-Audited Financial Results for the quarter ended June 30, 2026. The trading window for dealing in the company's securities will remain closed until August 15, 2026, and will reopen on August 16, 2026, in accordance with SEBI regulations and the company's insider trading code.

Brawn Biotech Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in effect from July 1, 2026, until 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended June 30, 2026. The company has advised insiders not to trade in its securities during this period. The exact date of the board meeting to consider these results will be communicated later.

Brawn Biotech Ltd. reports that Regulation 23(9) concerning the filing of related party transactions is not applicable for the year ended March 31, 2026. As of March 31, 2026, the company's paid-up share capital was ₹3 Crores and net worth was approximately ₹4.32 Crores. This exemption is based on Regulation 15(2) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as the company's financials remained below the threshold of ₹10 Crore paid-up capital and ₹25 Crore net worth for the last three consecutive financial years.

Brawn Biotech Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, in a meeting held on May 29, 2026. The company's revenue from operations for the year ended March 31, 2026, stood at ₹1,743.18 Lacs. The meeting commenced at 3:30 PM and concluded at 4:00 PM. The results have been prepared in compliance with Indian Accounting Standards.

Brawn Biotech Ltd. announced the audited financial results for the quarter and year ended 31st March 2026. The Board of Directors approved the results in their meeting held on 29th May 2026. Revenue from operations for the year ended March 31, 2026, stood at ₹1,697.77 Lacs. The meeting commenced at 3:30 PM and concluded at 4:00 PM.